Please select the option that best describes you:

How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?  

Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more